Applying deep learning architectures to de novo molecular drug design

1,197 views

|

October 30, 2018

  • Share
  • Dr Ola Engkvist, AstraZeneca, outlines how deep learning architectures are being applied to drug discovery

    Drug Discovery

    Keep up to date with all your favourite videos and channels.

    Get personalised notifications on new releases and channel content by subscribing to the LabTube eNewsletter.